E-DRUG: RFI: Reimbursement as barriers to Pharmaceutical Care (5)
-----------------------------------------------------------------
Hello John,
In general in Europe I think we use the original Strand/Hepler definition
(as the FIP does in its statements). That definition coves both disease
orientated as well as comprehensive PhC.
Looking at the programs that are currently being remunerated in
Europe, these concern disease oriented pharmaceutical care from
within the walls of the pharmacy.
There is a sort of remuneration for drug use review in the doctors'
practice in the UK. That, however, is not full blown PhC in my opinion.
The reimbursement issue seems to be linked to the proof of the
usefulness of PhC, especially in an economic sens. That blurs the
discussion because while you may improve the patients humanistic
and clinical outcomes, the insurance companies in general will only
look at costs and cost reduction.
Also, like in cinical studies, if pharmaceutical care is being provided on
a large scale in practice, will the payors accept that the benefits will be
the same as those demonstrated in a trial?
Foppe
Foppe van Mil, PhD, Pharm D. Pharmacy practice consultant
Margrietlaan 1, NL 9471 CT Zuidlaren, The Netherlands
Tel: +31 50 4029095. Fax +31 50 4090732
Email: jwfvmil@planet.nl
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug